TPEx is scheduled to hold a TPEx Listing Review Committee meeting on March 7, 2024 to review the listing application of Handa Pharmaceuticals, Inc.

Handa Pharmaceuticals, Inc. (stock code: 6620) is applying for listing on TPEx as a technology based enterprise. At the time of application, the company has capital in the amount of NT$1,411 million, its chairman is FANG-YU LIU, and its recommending securities firms include First Securities, KGI Securities, HORIZON Securities and SinoPac Securities.

Consolidated revenue, net loss after tax and loss per share of the applicant reports for FY 2022 were NT$198 million, NT$40 million, and NT$0.32 respectively. Consolidated revenue, net profit after tax and earnings per share of the applicant reports for the first three quarters of FY 2023 were NT$806 million, NT$640 million, and NT$4.83 respectively.